In the dose-escalation phase of our study , patients received vemurafenib 720 mg or 960 mg twice a day continuously and cobimetinib 60 mg , 80 mg , or 100 mg once a day for either 14 days on and 14 days off ( 14/14 ) , 21 days on and 7 days off ( 21/7 ) , or continuously ( 28/0 ) .